Book your appointment with us and receive confirmation within the day. *While stocks lasts.

Thank you for your interest in Sinopharm Covid-19 Vaccine.

Sinopharm COVID-19 Vaccine appointment booking is by online form submission or via WhatsApping us at +65 8868 7699.

关于中国国药新冠疫苗

中国国药集团新冠疫苗是一种名为 SARS-CoV-2 (Vero Cell)的灭活疫苗。它是使用更传统的灭活技术而研发和生产的针对新冠病毒(COVID-19 )的疫苗。世卫组织(WHO)免疫战略咨询专家组 (SAGE) ¹’² 完成了对疫苗的评估,建议18 岁及以上的成年人可分两次接种此疫苗,两次接种间隔三到四周。通过全面评估中国国药新冠疫苗的相关信息,专家组认为有足够证据证明该疫苗的安全性,以及其预防重症的能力,有效率达到79%

World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) ¹’² has also completed its review of the vaccine and recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks.
Vaccine efficacy for symptomatic and hospitalized disease was estimated to be 79%, all age groups combined.

中国国药新冠疫苗疫苗如何发挥作用?

中国国药新冠疫苗的工作原理是教会免疫系统产生针对新冠冠状病毒的抗体。 抗体附着在病毒蛋白上,例如镶嵌在其表面的所谓刺突蛋白。一旦接种了中国国药新冠疫苗 ,免疫系统就可以对活冠状病毒的感染做出反应。 B 细胞产生粘附在入侵者身上的抗体。 针对刺突蛋白的抗体可以防止病毒进入细胞¹。

Once vaccinated with Sinopharm Covid-19 vaccine, the immune system can respond to an infection of live coronaviruses. B cells produce antibodies that stick to the invaders. Antibodies that target the spike protein can prevent the virus from entering cells¹.

Source: World Health Organisation ³

中国国药新冠疫苗安全吗?

中国国药新冠疫苗(与所有世卫组织紧急使用清单 (EUL) Covid-19 疫苗¹一样)已根据质量、安全性和有效性进行了彻底的评估,并已推荐用于 18 岁及以上人群。 中国国药的临床试验表明,中国国药新冠疫苗可以保护人们免受 Covid-19 的侵害。 但目前还未有数据能说明这种保护能持续多久,抗体水平有可能会在几个月后下降。 但是,免疫系统还包含称为记忆 B 细胞的特殊细胞,这些细胞可能会保留有关冠状病毒的信息数年甚至数十年。 与 EUL 清单下的所有其他疫苗一样,中国国药将继续提交数据以确保疫苗持续的安全性和质量。

Sinopharm’s clinical trials have demonstrated that Covid-19 vaccine can protect people against Covid-19. But no one can yet say how long that protection lasts. It’s possible that the level of antibodies drops over the course of months. But the immune system also contains special cells called memory B cells that might retain information about the coronavirus for years or even decades. As with all vaccinations under the EUL, Sinopharm will continue to submit ongoing data for the continued safety and quality of the vaccine.

中国国药新冠疫苗的效果如何?

疫苗预防有症状的严重的新冠病毒感染的有效率为79%,对防止住院的有效率为79%。 根据世界卫生组织 ¹’² 的一项大规模、覆盖多国的三期试验结果表明,在间隔 21 天完成注射两剂国药疫苗的两周后,中国国药新冠疫苗对有症状的新冠病毒感染的有效率为 79%。 同时,临床实验报告了疫苗对防止住院治疗的有效率为 79%。

According to the WHO ¹’², a large, multi-country phase three trial showed after administering two doses at an interval of 21 days, the Sinopharm Covid-19 vaccine is 79% effective against symptomatic SARS-CoV-2 infection two weeks after the second dose. It was also reported to be 79% effective against hospitalisation.

谁有资格在新加坡接种中国国药新冠疫苗?

未在新加坡或其他地方接种过任何 Covid-19 疫苗的 18 岁及以上 ¹’² 符合条件的个人。 对中国国药新冠疫苗的任何成分有过敏史或体温超过 38.5ºC 的个人,不建议接种中国国药新冠疫苗。发烧者应推迟接种,直至不再发烧。 患有合并症、儿童、孕妇等特殊人群应咨询其保健医生并参考当前国家推荐的疫苗接种标准,以确定是否适合接种中国国药新冠疫苗。

Sinopharm Covid-19 vaccine is not recommended for individuals with a history of anaphylaxis to any component of the Sinopharm Covid-19 vaccine or have body temperature over 38.5ºC should postpone vaccination until they no longer have a fever. Special population group of such as individuals with comorbidities, children and pregnant woman should check with their healthcare physician and refer to current country’s recommended vaccination criteria to determine if suitable for Sinopharm Covid-19 Vaccine.

重要事实

世卫组织(WHO ¹’² )建议第一剂和第二剂之间间隔3-4周。建议所有接种疫苗的人接种两剂。与此同时,在各国进行的临床试验中仍在评估额外剂量的必需性和接种时间。

参考文献
1. The Sinopharm COVID-19 vaccine: What you need to know (2021, May 7). Retrieved July 27 2021 https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
2. Wilder-Smith, A., Hombach, J., Marti, M., & O’Brien, K. (2021, May 24). Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm. Retrieved July 27, 2021, from World Health Organisation website: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BIBP-2021.1
3. COVID-19 advice for the public: Getting vaccinated (2021, July). Retrieved July 28 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice
Disclaimer:
本网站所包含的信息包括但不限于文本、图形、图像和其他材料,仅用于教育目的,基于公开信息,并根据 Medic Surgical & Laser Clinic 的现有知识而准备。本网站上的任何材料均不得取代专业的医疗建议。如果您有任何与医疗状况有关的问题,或者您是否有资格接种上述疫苗,请始终寻求您的医生或其他合格医疗保健专业人员的建议。

Medic Surgical & Laser Clinic 致力于保护您的隐私。我们严格保密您提供的所有个人数据,并且只会以向您提供健康相关新闻更新和服务更新(包括但不限于 Covid-19 疫苗)的方式使用您的个人数据。所有对“Medic Surgical & Laser Clinic”、“我们”、“我们的”和“我们的”的提及统称为 Medic Surgical & Laser Clinic 及其所有联营公司,以及母控股公司 Clearbridge Medical Group。
Medic Surgical & Laser Clinic is committed to safeguarding your privacy. We treat all personal data provided by you in strict confidence, and will only use your personal data in the manner of providing you updates of health-related news and updates of services including and not limited to Covid-19 Vaccine. All references to the “Medic Surgical & Laser Clinic”, “we”, “us” and “our” refer collectively to the Medic Surgical & Laser Clinic, and all its associates, and Clearbridge Medical Group, the parent holding company.
Chinese